Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEHR NASDAQ:EYPT NASDAQ:TXG NYSE:VNT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEHRAehr Test Systems$84.42-15.2%$64.54$8.31▼$108.75$2.65B3.262.40 million shs3.42 million shsEYPTEyepoint Pharmaceuticals$11.81-4.4%$13.78$5.45▼$19.11$989.31M1.761.18 million shs493,686 shsTXG10x Genomics$21.70+2.4%$21.40$8.06▼$26.44$2.74B2.052.60 million shs1.61 million shsVNTVontier$27.99-0.2%$35.39$27.76▼$48.20$3.94B1.241.29 million shs1.26 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEHRAehr Test Systems0.00%+2.33%+18.65%+245.01%+971.04%EYPTEyepoint Pharmaceuticals0.00%-9.59%-17.28%-4.56%+101.47%TXG10x Genomics0.00%-1.85%-18.71%+17.00%+125.77%VNTVontier0.00%-6.93%-24.85%-33.00%-24.34%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEHRAehr Test Systems$84.42-15.2%$64.54$8.31▼$108.75$2.65B3.262.40 million shs3.42 million shsEYPTEyepoint Pharmaceuticals$11.81-4.4%$13.78$5.45▼$19.11$989.31M1.761.18 million shs493,686 shsTXG10x Genomics$21.70+2.4%$21.40$8.06▼$26.44$2.74B2.052.60 million shs1.61 million shsVNTVontier$27.99-0.2%$35.39$27.76▼$48.20$3.94B1.241.29 million shs1.26 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEHRAehr Test Systems0.00%+2.33%+18.65%+245.01%+971.04%EYPTEyepoint Pharmaceuticals0.00%-9.59%-17.28%-4.56%+101.47%TXG10x Genomics0.00%-1.85%-18.71%+17.00%+125.77%VNTVontier0.00%-6.93%-24.85%-33.00%-24.34%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEHRAehr Test Systems 2.40Hold$68.00-19.45% DownsideEYPTEyepoint Pharmaceuticals 3.00Buy$31.80169.26% UpsideTXG10x Genomics 2.33Hold$23.176.75% UpsideVNTVontier 2.50Moderate Buy$42.3851.42% UpsideCurrent Analyst Ratings BreakdownLatest EYPT, VNT, AEHR, and TXG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2026TXG10x Genomics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$20.00 ➝ $22.005/12/2026TXG10x Genomics JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$17.00 ➝ $20.005/11/2026VNTVontier EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$36.005/8/2026VNTVontier Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$37.005/8/2026VNTVontier CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$50.00 ➝ $44.005/8/2026VNTVontier BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$50.00 ➝ $45.005/8/2026VNTVontier KeyCorpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$50.00 ➝ $40.005/7/2026EYPTEyepoint Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$39.00 ➝ $37.005/4/2026AEHRAehr Test Systems Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Sell (D+)4/21/2026EYPTEyepoint Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026AEHRAehr Test Systems Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)(Data available from 5/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEHRAehr Test Systems$58.97M45.02$0.09 per share925.42$4.13 per share20.44EYPTEyepoint Pharmaceuticals$31.37M31.56N/AN/A$3.70 per share3.19TXG10x Genomics$638.78M4.31N/AN/A$6.24 per share3.48VNTVontier$3.08B1.28$4.21 per share6.65$8.84 per share3.17Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEHRAehr Test Systems-$3.91M-$0.38N/AN/AN/A-25.23%-7.15%-6.15%7/14/2026 (Estimated)EYPTEyepoint Pharmaceuticals-$231.96M-$3.50N/AN/AN/A-3,566.63%-110.54%-90.15%8/5/2026 (Estimated)TXG10x Genomics-$43.54M-$0.17N/AN/AN/A-3.55%-2.86%-2.23%8/6/2026 (Estimated)VNTVontier$406.10M$2.839.897.561.0813.37%37.88%10.90%7/30/2026 (Estimated)Latest EYPT, VNT, AEHR, and TXG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026TXG10x Genomics-$0.29-$0.10+$0.19-$0.10$146.41 million$150.84 million5/7/2026Q1 2026VNTVontier$0.82$0.80-$0.02$0.66$737.21 million$750.60 million5/6/2026Q1 2026EYPTEyepoint Pharmaceuticals-$0.79-$0.99-$0.20-$0.99$0.35 million$0.70 million4/7/2026Q3 2026AEHRAehr Test Systems-$0.07-$0.05+$0.02-$0.10$10.85 million$10.31 million3/4/2026Q4 2025EYPTEyepoint Pharmaceuticals-$0.78-$0.8143-$0.0343-$0.81$1.01 million$0.62 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAEHRAehr Test SystemsN/AN/AN/AN/AN/AEYPTEyepoint PharmaceuticalsN/AN/AN/AN/AN/ATXG10x GenomicsN/AN/AN/AN/AN/AVNTVontier$0.100.36%N/A3.53%N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEHRAehr Test SystemsN/A10.976.26EYPTEyepoint PharmaceuticalsN/A6.666.63TXG10x GenomicsN/A5.905.42VNTVontier1.261.230.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEHRAehr Test Systems69.69%EYPTEyepoint Pharmaceuticals99.41%TXG10x Genomics84.68%VNTVontier95.83%Insider OwnershipCompanyInsider OwnershipAEHRAehr Test Systems6.80%EYPTEyepoint Pharmaceuticals4.46%TXG10x Genomics8.84%VNTVontier1.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEHRAehr Test Systems9031.45 million29.31 millionOptionableEYPTEyepoint Pharmaceuticals12083.84 million80.10 millionOptionableTXG10x Genomics1,240126.96 million115.73 millionOptionableVNTVontier7,800140.80 million139.25 millionOptionableEYPT, VNT, AEHR, and TXG HeadlinesRecent News About These CompaniesVontier CorpMay 17 at 2:52 PM | edition.cnn.comVontier’s Gilbarco Veeder-Root Secures Back-to-Back Large India Tenders With India Oil CorporationMay 15 at 4:22 AM | businesswire.comVontier Corporation VNT Stock Forecast & Price TargetMay 15 at 4:22 AM | finance.yahoo.comVontier (VNT) price target decreased by 11.38% to 43.33May 15 at 4:22 AM | msn.comVontier Corporation (NYSE:VNT) Receives Average Recommendation of "Moderate Buy" from AnalystsMay 14, 2026 | americanbankingnews.comVNT Q1 Deep Dive: Cautious Guidance and Divestiture Shape Outlook Despite Core Segment StrengthMay 12, 2026 | finance.yahoo.comVontier’s Driivz Partners to Scale Duracell E-Charge Ultra-Fast Network Across the UKMay 11, 2026 | 01net.it0Analyzing DIH Holding US (OTCMKTS:DHAI) & Vontier (NYSE:VNT)May 11, 2026 | americanbankingnews.comVontier Reshapes Portfolio With Teletrac Navman Sale And Patheon ExpansionMay 10, 2026 | finance.yahoo.comCitigroup Lowers Vontier (NYSE:VNT) Price Target to $44.00May 10, 2026 | americanbankingnews.comVontier Corporation $VNT Shares Sold by Horizon Investments LLCMay 9, 2026 | marketbeat.comDanske Bank A S Reduces Stake in Vontier Corporation $VNTMay 9, 2026 | marketbeat.comVontier (NYSE:VNT) Downgraded to "Hold" Rating by Wall Street ZenMay 9, 2026 | marketbeat.comVontier (NYSE:VNT) Given New $44.00 Price Target at CitigroupMay 8, 2026 | marketbeat.comVontier's DRB Selected by Super Star Car Wash for 118-Site Software TransformationMay 8, 2026 | tmcnet.comBarclays Lowers Vontier (NYSE:VNT) Price Target to $45.00May 8, 2026 | marketbeat.comKeyCorp Lowers Vontier (NYSE:VNT) Price Target to $40.00May 8, 2026 | marketbeat.comVontier (NYSE:VNT) Issues Quarterly Earnings ResultsMay 7, 2026 | marketbeat.comVontier Corporation (VNT) Q1 2026 Earnings Call TranscriptMay 7, 2026 | seekingalpha.comVontier (VNT) Q1 2026 Earnings TranscriptMay 7, 2026 | finance.yahoo.comVontier Corporation 2026 Q1 - Results - Earnings Call PresentationMay 7, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 20265 Stocks Positioned to Win the AI Data Center BuildoutBy Bridget Bennett | April 20, 2026AMD’s Breakout Isn’t the Story—This Catalyst IsBy Thomas Hughes | April 24, 2026Insider Trades: Nike Sees More CEO Buys, Aehr Sold on 300% GainBy Leo Miller | April 20, 2026Aehr Test Systems: Small AI Stock Sees Record AI Hyperscaler OrderBy Leo Miller | April 22, 2026EYPT, VNT, AEHR, and TXG Company DescriptionsAehr Test Systems NASDAQ:AEHR$84.42 -15.08 (-15.15%) As of 03:43 PM Eastern This is a fair market value price provided by Massive. Learn more.Aehr Test Systems provides test solutions for testing, burning-in, and semiconductor devices in wafer level, singulated die, and package part form, and installed systems worldwide. Its product portfolio includes FOX-XP and FOX-NP systems that are full wafer contact and singulated die/module test and burn-in systems that can test, burn-in, and stabilize range of devices, including silicon carbide-based and other power semiconductors, 2D and 3D sensors used in mobile phones, tablets and other computing devices, memory semiconductors, processors, microcontrollers, systems-on-a-chip, and photonics and integrated optical devices. The company also offers FOX-CP system, a low-cost single-wafer compact test solution for logic, memory, and photonic devices; FOX WaferPak Contactor, a full wafer contactor capable of testing wafers up to 300mm that enables integrated circuit manufacturers to perform test, burn-in, and stabilization of full wafers on the FOX-P systems. In addition, it provides FOX DiePak Carrier, a reusable temporary package that enables IC manufacturers to perform final test and burn-in of bare die and modules; and FOX DiePak Loader. The company was incorporated in 1977 and is headquartered in Fremont, California.Eyepoint Pharmaceuticals NASDAQ:EYPT$11.81 -0.54 (-4.37%) As of 03:43 PM Eastern This is a fair market value price provided by Massive. Learn more.EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.10x Genomics NASDAQ:TXG$21.70 +0.50 (+2.37%) As of 03:43 PM Eastern This is a fair market value price provided by Massive. Learn more.10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.Vontier NYSE:VNT$27.98 -0.05 (-0.16%) As of 03:43 PM Eastern This is a fair market value price provided by Massive. Learn more.Vontier Corporation provides mobility ecosystem solutions worldwide. The company operates through Mobility Technologies, Repair Solutions, and Environmental and Fueling Solutions segments. The Mobility Technologies segment provides digitally equipment solutions for mobility ecosystem, such as point-of-sale and payment systems, workflow automation, telematics, data analytics, software platform, and integrated solutions for alternative fuel dispensing. The Repair Solutions segment manufactures and distributes vehicle repair tools, toolboxes, automotive diagnostic equipment and software through mobile franchise network. The Environmental and Fueling Solutions segment offers environmental, fueling hardware, software, and aftermarket solutions for fueling infrastructures. It also offers a range of solutions, including environmental sensors; fueling equipment; field payment hardware; point-of sale, workflow, and monitoring software; vehicle tracking and fleet management; software solutions for EV charging; and vehicle mechanics, and technicians equipment. The company markets its products and services to retail and commercial fueling, convenience store, and car wash operators; commercial vehicle repair businesses, fleet owners/operators and electric vehicle charging network operators, as well as direct sales personnel and independent distributors. It serves customers in North America, the Asia Pacific, Europe, and Latin America. Vontier Corporation was incorporated in 2019 and is headquartered in Raleigh, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Applied Optoelectronics Stock May Be Near a Turning Point Is Everspin Technologies the Next AI Edge Breakout? 5 Robotics Stocks to Watch as Physical AI Builds Momentum Willing and Abel: Berkshire's New CEO Makes Huge Portfolio Changes in Q1 Peloton Stock Gives Back Gains After Upbeat Earnings Report 3 Infrastructure Stocks Fueling the Data Center Building Boom MarketBeat Week in Review – 05/11 - 05/15 Insider Buying Says Upstart Isn’t Down for the Count Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
